Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 13Recruiting 8Not yet recruiting 3Completed 3

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Tumor-Agnostic 3Head & Neck 3Breast 3Sarcoma 2Gynecologic 2CNS 2Other solid neoplasm 1Endocrine 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × anlotinib × Breast × Clear all
NCT04877821 2026-04-02

NeoSACT

Guangdong Provincial People's Hospital

Phase 2 Completed
29 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Hunan Cancer Hospital

Phase 2 Completed
80 enrolled
Breast

Breast Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Completed
26 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡